Page 2 - Drug Controller General Of India

DCGI approves indigenous mRNA Covid jab for emergency use in adults: Report

It is for the first time ever that Covid-19 vaccine remains stable during storage even at 2-8 degrees Celsius

CBI apprehends some persons over Rs 3 lakh bribery case at DCGI office

The CBI team, after getting inputs about exchange of bribery, allegedly carried out trap operation in which some persons were apprehended, officials said.

Centre's FY22 fiscal deficit at 6.7% vs revised estimates of 6.9%

April saw revenue surplus of Rs 591 crore

'Gennova will soon submit necessary data of mRNA Covid vaccine to DCGI'

The vaccine - GEMCOVAC-19 - is the country's first homegrown mRNA Covid- 19 vaccine and is seen as a game-changer for the healthcare industry.

DCGI emergency use nod for Covaxin, Corbevax and ZyCoV-D across age groups

Covaxin bags approval for 6-12-year age group, Corbevax for 5-12 group, and ZyCoV-D for 12 years and above

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds

This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years

Zydus gets DCGI nod for drug to treat anaemia linked with kidney disease

Zydus Lifesciences on Monday said it has received an approval from the DCGI for Oxemia (Desidustat), a first-of-its-kind oral treatment for anaemia associated with chronic kidney disease

Sputnik Light: SEC recommends permission for phase 3 trial as booster dose

The DCGI had on February 4 granted emergency use permission to Sputnik Light vaccine in India, subject to certain regulatory provisions

Govt panel recommends EUA for Covid vaccine Covovax for 12-17 age group

An expert panel of the country's central drug authority has recommended granting emergency use authorisationto SII's Covid vaccine Covovax for the 12-17 age group, official sources said on Friday.

Corbevax Covid vaccine is safe, offers high antibody levels: NTAGI chief

India's third homegrown COVID-19 vaccine Corbevax is safe and offers good immunogenicity and higher antibody levels than some other vector vaccines: Official

DCGI accords conditional market approval for Covaxin and Covishield

Firms will need to submit data of overseas ongoing clinical trials of their vaccines every 6 months

Stempeutics gets DCGI nod for Phase 3 trial to treat Covid patients

Stempeutics said it has received DCGI clearance to conduct Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

Biological E gets approval to conduct trials of Corbevax as booster dose

DCGI has given approval to the Hyderbad-based pharmaceutical company Biological E to conduct phase 3 clinical trials

Ensure Covaxin availability if cocktail policy for booster is adopted: IMA

IMA said that the Centre should ensure the large-scale availability of Covaxin if a mixed match policy is adopted for booster doses for healthcare workers

Decision to vaccinate children 'unscientific': Senior AIIMS epidemiologist

A senior epidemiologist at AIIMS termed the Centre's decision to vaccinate children against Covid "unscientific" and said it will not yield any additional benefit

India would need nearly 250 million more doses to cover new cohorts

Nearly 40 per cent of the 76 million children between the ages of 15 and 18 reside in states where the vaccination pace has been slowest

Bharat Biotech seeks approval for Phase 3 trials of intranasal vaccine

Bharat Biotech has sought the approval of the Drug Controller General of India (DCGI) to conduct Phase 3 trials of its Covid-19 intranasal vaccine

Health regulatory agencies likely to come under DCGI ambit

Single-window system to take care of regulatory need for drugs, vaccines

Covid: DCGI approves Hetero's Tocilizumab for hospitalised adults

Hetero, a globally renowned vertically integrated pharmaceutical organization, on Monday announced that the DCGI has issued EUA for the generic version of Tocilizumab in India

DCGI nod to phase-I clinical trial of Reliance Life Sciences' Covid vaccine

DCGI on Friday granted permission to the Mukesh Ambani-owned Reliance Life Sciences to conduct phase-I clinical trial of its indigenous COVID-19 vaccine with certain conditions, sources said.